Free Trial
NASDAQ:CDXC

ChromaDex (CDXC) Stock Price, News & Analysis

ChromaDex logo

About ChromaDex Stock (NASDAQ:CDXC)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$5.26
$8.55
52-Week Range
N/A
Volume
554,788 shs
Average Volume
828,973 shs
Market Capitalization
$611.50 million
P/E Ratio
787.29
Dividend Yield
N/A
Price Target
$9.03
Consensus Rating
Buy

Company Overview

ChromaDex Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
63rd Percentile Overall Score

CDXC MarketRank™: 

ChromaDex scored higher than 63% of companies evaluated by MarketBeat, and ranked 375th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    ChromaDex has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    ChromaDex has received no research coverage in the past 90 days.

  • Read more about ChromaDex's stock forecast and price target.
  • Earnings Growth

    Earnings for ChromaDex are expected to grow by 200.00% in the coming year, from $0.04 to $0.12 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of ChromaDex is 787.29, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.85.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of ChromaDex is 787.29, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.26.

  • Short Interest

    There is no current short interest data available for CDXC.
  • Dividend Yield

    ChromaDex does not currently pay a dividend.

  • Dividend Growth

    ChromaDex does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for CDXC.
    • Insider Buying vs. Insider Selling

      In the past three months, ChromaDex insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      Only 9.64% of the stock of ChromaDex is held by insiders.

    • Percentage Held by Institutions

      Only 15.41% of the stock of ChromaDex is held by institutions.

    • Read more about ChromaDex's insider trading history.
    Receive CDXC Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for ChromaDex and its competitors with MarketBeat's FREE daily newsletter.

    CDXC Stock News Headlines

    The Trump Dump is starting; Get out of stocks now?
    The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
    ChromaDex to Present at the 37th Annual Roth Conference
    ChromaDex price target raised to $11 from $8 at H.C. Wainwright
    See More Headlines

    CDXC Stock Analysis - Frequently Asked Questions

    ChromaDex Co. (NASDAQ:CDXC) posted its quarterly earnings data on Thursday, October, 31st. The company reported $0.02 EPS for the quarter, beating the consensus estimate of $0.01 by $0.02. The firm earned $25.58 million during the quarter, compared to the consensus estimate of $23.70 million. ChromaDex had a trailing twelve-month return on equity of 4.85% and a net margin of 1.62%.
    Read the conference call transcript
    .

    Shares of CDXC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that ChromaDex investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH).

    Company Calendar

    Last Earnings
    10/31/2024
    Today
    7/12/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    Medicinals & botanicals
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:CDXC
    CIK
    1386570
    Employees
    120
    Year Founded
    N/A

    Price Target and Rating

    High Price Target
    $11.00
    Low Price Target
    $8.00
    Consensus Rating
    Buy
    Rating Score (0-4)
    3.00
    Research Coverage
    3 Analysts

    Profitability

    EPS (Trailing Twelve Months)
    $0.10
    Trailing P/E Ratio
    787.29
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    -$4.94 million
    Net Margins
    1.62%
    Pretax Margin
    1.62%
    Return on Equity
    4.85%
    Return on Assets
    2.70%

    Debt

    Debt-to-Equity Ratio
    N/A
    Current Ratio
    2.95
    Quick Ratio
    2.35

    Sales & Book Value

    Annual Sales
    $99.60 million
    Price / Sales
    0.00
    Cash Flow
    N/A
    Price / Cash Flow
    N/A
    Book Value
    $0.38 per share
    Price / Book
    N/A

    Miscellaneous

    Outstanding Shares
    77,750,000
    Free Float
    69,020,000
    Market Cap
    $611.50 million
    Optionable
    Optionable
    Beta
    2.21

    Social Links

    Elon Musk's Next Move Cover

    Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

    Get This Free Report

    This page (NASDAQ:CDXC) was last updated on 7/13/2025 by MarketBeat.com Staff
    From Our Partners